标题
New NS5B polymerase inhibitors for hepatitis C
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 8, Pages 963-975
出版商
Informa Healthcare
发表日期
2010-07-15
DOI
10.1517/13543784.2010.500285
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 1034 COMBINATION OF TWO COMPLEMENTARY NUCLEOTIDE ANALOGUES PSI-7977 AND PSI-938 EFFECTIVELY CLEARS WILD TYPE AND NS5B:S282T HCV REPLICONS – COMPARISON WITH COMBINATIONS OF OTHER ANTIVIRAL COMPOUNDS
- (2010) V. Zennou et al. JOURNAL OF HEPATOLOGY
- 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS
- (2010) M. Rodriguez-Torres et al. JOURNAL OF HEPATOLOGY
- 2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS
- (2010) J. Lalezari et al. JOURNAL OF HEPATOLOGY
- Cyclophilin Inhibitors
- (2009) Philippe A. Gallay Clinics in Liver Disease
- The antiviral activity of toll-like receptor 7 and 7/8 agonists
- (2009) R.L. Miller et al. DRUG NEWS & PERSPECTIVES
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
- (2009) Christoph Sarrazin et al. GASTROENTEROLOGY
- Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial
- (2009) Stuart K. Roberts et al. HEPATOLOGY
- 940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS
- (2009) C. Cooper et al. JOURNAL OF HEPATOLOGY
- 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION
- (2009) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- 1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1
- (2009) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- 1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1
- (2009) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- 1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS
- (2009) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- 968 GENOTYPIC CHARACTERISATION OF HCV NS5B FOLLOWING 8-DAY MONOTHERAPY WITH THE POLYMERASE INHIBITOR PF-00868554 IN HCV-INFECTED SUBJECTS
- (2009) P. Troke et al. JOURNAL OF HEPATOLOGY
- 323 PRECLINICAL PHARMACOKINETIC AND SAFETY PROFILE OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
- (2009) S.S. Good et al. JOURNAL OF HEPATOLOGY
- 970 PRECLINICAL CHARACTERIZATION OF ABT-072: A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
- (2009) R. Wagner et al. JOURNAL OF HEPATOLOGY
- 958 NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS
- (2009) S. Le Pogam et al. JOURNAL OF HEPATOLOGY
- 961 GENOTYPIC AND PHENOTYPIC ANALYSIS OF HCV NS5B VARIANTS SELECTED FROM PATIENTS TREATED WITH VCH-916
- (2009) O. Nicolas et al. JOURNAL OF HEPATOLOGY
- Evaluation of VCH-759 monotherapy in hepatitis C infection
- (2009) Curtis Cooper et al. JOURNAL OF HEPATOLOGY
- Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy
- (2009) Florence Legrand-Abravanel et al. JOURNAL OF MEDICAL VIROLOGY
- Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees
- (2008) S. S. Carroll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors
- (2008) K. J. Herlihy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
- (2008) M. F. McCown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treating hepatitis C in the prison population is cost-saving
- (2008) Jennifer A. Tan et al. HEPATOLOGY
- R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
- (2008) Paul J. Pockros et al. HEPATOLOGY
- Correction
- (2008) HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
- Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests
- (2008) Jessica D. Korman et al. HEPATOLOGY
- Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
- (2008) S. Le Pogam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS
- (2008) J. Lalezari et al. JOURNAL OF HEPATOLOGY
- 67 POTENT ANTIVIRAL ACTIVITY OF SECOND GENERATION NUCLEOSIDE INHIBITORS, IDX102 AND IDX184, IN HCV-INFECTED CHIMPANZEES
- (2008) D.N. Standring et al. JOURNAL OF HEPATOLOGY
- Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process
- (2008) Bruno Gagliardo et al. JOURNAL OF HEPATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started